TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06542835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video text message
Description: Video text messages tailored to the Latinx population to educate and motivate patients to complete CRC screening.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-clinic CRC screening promotion
Description: Stool-test orders, colonoscopy referrals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mailed FIT
Description: Mailed FIT kits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social needs navigation
Description: Patient navigation to address social needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminders
Description: Centralized text and/or telephone reminders for ordered tests.
Study: NCT06590194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH009-1 tablet
Description: PH009-1 will be administered in fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH009-1 tablet
Description: PH009-1 will be administered in fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH009-1 tablet
Description: PH009-1 will be administered in fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH009-1 tablet
Description: PH009-1 will be administered in fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH009-1 tablet
Description: PH009-1 will be administered in fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH009-1 tablet
Description: PH009-1 will be administered in fasting state
Study: NCT06604065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMS2434 (amino acids)
Description: The proprietary composition includes leucine, valine, isoleucine, lysine, phenylalanine, threonine, tyrosine, histidine, and methionine. Small amounts of non-caloric flavorings are also included.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched non-caloric placebo. Study products will be in powder form and packaged in individual serving sizes and will be dissolved in 8 oz water for consumption.
Study: NCT06585852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGD
Description: Study group main material

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenograft
Description: Scaffold material of choice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenograft
Description: Scaffold material of choice

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Split crest technique
Description: Piezoelectric surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Split crest technique
Description: Piezoelectric surgery
Study: NCT06597318

Intervention type: OTHER
Intervention: Hospitalization
Description: The investigators collect PROMs amongst up to 1000 patients in general internal medicine divisions of all five Swiss university hospitals
Study: NCT06585956

Intervention type: BEHAVIORAL
Intervention: Comminication via Telemedicine
Description: Comminication via Telemedicine With Patients
Study: NCT06187194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRE System
Description: Irreversible Electroporation (IRE) System for Tonsil Reduction for The Treatment of Chronic Symptomatic Tonsillar Hypertrophy
Study: NCT06585956

Intervention type: BEHAVIORAL
Intervention: Information
Description: Informing the patient and their relatives
Study: NCT06088069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Patients will be virtually immersed into a natural universe and soft music for 15 minutes preoperatively and during surgery.
Study: NCT05285371

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urinalysis (UA)
Description: Urinalysis will be performed twice daily starting on Postoperative Day 0.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Urinalysis (UA)
Description: Urinalysis will be performed twice daily starting on Postoperative Day 0.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Complete Metabolic Panel (CMP)
Description: A CMP will be performed on Postoperative Day 2 and Postoperative Day 4.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Complete Metabolic Panel (CMP)
Description: A CMP will be performed on Postoperative Day 2 and Postoperative Day 4.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glucose Stick Test (d-Stick)
Description: A d-Stick will be performed twice daily except on Postoperative Day 2 and Postoperative Day 4 as the CMP includes serum glucose levels.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Glucose Stick Test (d-Stick)
Description: A d-Stick will be performed twice daily except on Postoperative Day 2 and Postoperative Day 4 as the CMP includes serum glucose levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: A medical chart review will be performed for all subjects enrolled.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Medical Chart Review
Description: A medical chart review will be performed for all subjects enrolled.
Study: NCT06598111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amplified Benefits
Description: Participants write a brief, detailed narrative describing a day in their future if they did not restrict their caloric intake and were not concerned about their body weight or shape.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amplified Benefits
Description: Participants write a brief, detailed narrative describing a day in their future if they did not restrict their caloric intake and were not concerned about their body weight or shape.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amplified Consequences
Description: Participants complete the Pros and Cons of Anorexia scale to amplify the consequences of restrictive eating. They are also presented with blurbs about the consequences of restrictive eating.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amplified Consequences
Description: Participants complete the Pros and Cons of Anorexia scale to amplify the consequences of restrictive eating. They are also presented with blurbs about the consequences of restrictive eating.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants write a brief narrative considering a future free of concern about finances.
Study: NCT05038098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrectomy
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrectomy
Description: Undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Given peritumorally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Given peritumorally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron Conjugated Polymers in Saline Suspension
Description: Given peritumorally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron Conjugated Polymers in Saline Suspension
Description: Given peritumorally
Study: NCT05320445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Expressive Group Therapy
Description: The SEGT is a six-module program where each session is approximately one hour, and is held twice a week over a three-week period. It is framed within social cognitive theory, whereby resilience to adversity (NMSK trauma in this instance) relies on personal enablement. Enablement serves to equip the individual with the personal resources to cultivate their self-efficacy and mastery and to select and construct environments that promote successful adaption.
Study: NCT06604455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure/relaxation with acupuncture
Description: The acupressure/acupuncture points will be designated based on evidence-based research. For example, clinical guideline-based integrative oncology protocol for pain relief will include the following analgesia-related acupressure/acupuncture points: Liver-3, Taichong; Large-Intestine 4, Hegu; Stomach-36, Zusanli; Pericard-6, Neiguan; Spleen-6, Sanyinjiao; Yin tang; as well as battlefield ear acupuncture points. In both intervention groups, relaxation techniques will be tailored to the patient's quality of life related concerns, with the option of including breathing and guided imagery modalities as well.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure/relaxation
Description: The acupressure points will be designated based on evidence-based research. In both intervention groups, relaxation techniques will be tailored to the patient's quality of life related concerns, with the option of including breathing and guided imagery modalities as well.
Study: NCT05387239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VL-PX10 and VL-P22 plus standard care
Description: The treatment consists of administration of VL-P22 and VL-PX10 plus standard care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline plus standard care
Study: NCT05092100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual stimulus similarity
Description: Visual stimulus similarity will be varied in order to test for effects on memory. Learning protocol (the order and frequency with which stimuli are learned) will also be varied.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual stimulus similarity
Description: Visual stimulus similarity will be varied in order to test for effects on memory. Learning protocol (the order and frequency with which stimuli are learned) will also be varied.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual stimulus similarity
Description: Visual stimulus similarity will be varied in order to test for effects on memory. Learning protocol (the order and frequency with which stimuli are learned) will also be varied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: fMRI will be used to measure patterns of BOLD activity during learning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye tracking
Description: Eye tracking will be used to measure patterns of eye movements when viewing images.
Study: NCT05170919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Patients will be prescribed a dosage of 15 mg per day. Dose will not be escalated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: the participant will be prescribed a dosage of 2.5mg per day if \> 65 yrs. and 5 mg/per day if \<65 yrs. per day. Per physician discretion, participants are allowed a dose escalation of a maximum of 10mg.
Study: NCT05860946

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Remote ischemic conditioning
Description: The RIC intervention included five cycles of 5 min inflating tourniquets with the pressure of 200 mmHg and 5 min deflating with pressure of 0 mmHg alternately

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: The RIC intervention included five cycles of 5 min inflating tourniquets with the pressure of 200 mmHg and 5 min deflating with pressure of 0 mmHg alternately
Study: NCT05879354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Cycle of Breathing Techniques
Description: Patients in the intervention group will be provided with video-guided Active Cycle of Breathing Techniques twice a day for 28 days.
Study: NCT05893745

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise Program
Description: Participants in the control group will receive a supervised exercise program that consists of three weekly sessions in addition to home exercises, over the course of four weeks. This program will include stabilization, flexing, extension, and rotation exercises for the cervical region and self-mobilization targeting the deep neck muscles. Participants will be instructed to perform the exercises at home three times a week in a manner that did not cause pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Program plus Dermoneuromodulation Techniques
Description: Participants in the study group will receive the same supervised exercise program as the control group, with home exercises, in addition to two dermoneuromodulation techniques for the Dorsal Cutaneous Nerve (C3-T1), which are the skin stretch technique and kitten technique. Patients in this group will receive 3 sessions/week for a total of 4 weeks.
Study: NCT06139016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual reality gear and content will be used to affect and control the audiovisual perception of patients during a single treatment with ketamine/esketamine
Study: NCT04911140

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation twice a week
Description: The photobiomodulation will be applied with a LED facial mask, Cosmedical brand (São Paulo, Brazil), containing 92 red LEDs, 660 nm of wavelength, in continuous mode for 21 minutes, twice a week, for 4 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation three times a week
Description: The photobiomodulation will be applied with a LED facial mask, Cosmedical brand (São Paulo, Brazil), containing 92 red LEDs, 660 nm of wavelength, in continuous mode for 21 minutes, three times a week, for 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Simulated Photobiomodulation
Description: Photobiomodulation will be simulated, with the device turned off, twice a week, for 4 weeks. The characteristic sound of the device will be triggered by recording.
Study: NCT04912258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans arterial chemoembolization with Irinotecan Drug-eluting Beads
Description: preoperative chemoembolization with Irinotecan Drug-eluting Beads
Study: NCT05686902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLEANING SOLUTION
Description: The difference in peristomal skin integrity between the groups will be examined.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CLEANING SOLUTION
Description: The difference in peristomal skin integrity between the groups will be examined.
Study: NCT03878251

Intervention type: DEVICE
Group type: OTHER
Intervention: Quantitative attention evaluation criteria in intellectual disability
Description: Quantitative interactive attention evaluation tests by using games on touchscreen and or eye tracking (oculometer)

Intervention type: DEVICE
Group type: OTHER
Intervention: Quantitative attention evaluation criteria in intellectual disability
Description: Quantitative interactive attention evaluation tests by using games on touchscreen and or eye tracking (oculometer)

Intervention type: DEVICE
Group type: OTHER
Intervention: Quantitative attention evaluation criteria in intellectual disability
Description: Quantitative interactive attention evaluation tests by using games on touchscreen and or eye tracking (oculometer)

Intervention type: DEVICE
Group type: OTHER
Intervention: Quantitative attention evaluation criteria in intellectual disability
Description: Quantitative interactive attention evaluation tests by using games on touchscreen and or eye tracking (oculometer)
Study: NCT05589948

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Radicle Calm Study Placebo Control 1
Description: Participants will use their Radicle Calm Placebo Control Product 1 as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Radicle Calm Study Placebo Control 2
Description: Participants will use their Radicle Calm Placebo Control Product 2 as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Radicle Calm Study Active Product 1.1
Description: Participants will use their Radicle Calm Active Product 1.1 as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Radicle Calm Study Active Product 2.1
Description: Participants will use their Radicle Calm Active Product 2.1 as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Radicle Calm Study Active Product 2.2
Description: Participants will use their Radicle Calm Active Product 2.2 as directed for a period of 4 weeks.
Study: NCT04826861

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SLIM intervention
Description: Core components: 1) goal setting, 2) motivational interviewing, 3) feedback, 4) health technology
Study: NCT05714098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gerofit Exercise Program
Description: The tele-Gerofit exercise intervention has training focused on meeting the physical activity guidelines and incorporating cardiovascular, strength, and balance training. Sessions will also include a mindfulness component, warm up, cool-down, and safety checks. Exercises are personalized to each person's functional status. Intensity of exercises will be determined by participants providing a rating of perceived exertion (RPE) on a scale of 0 (easy) to 10 (very hard) throughout the session. Initial exercise sessions will start at low-intensity and will gradually increase the duration and intensity to allow each person to reach recommended exercise levels at their own pace. Exercises are done virtually via Zoom. Each cohort will have 5-8 participants. The exercise program will be optimized after each cohort with modifications based on participant and exercise expert feedback.
Study: NCT06153927

Intervention type: DIAGNOSTIC_TEST
Intervention: CT-FFR
Description: CT-FFR was calculated using HeartMedi+ 1.0 according to the manufacturer's instructions
Study: NCT05019326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andrographis Paniculata
Description: Andrographis extract, equivalent to andrographolide 20 mg per capsule, for a total of 180 mg of andrographolide per day, dosing into 3 capsules taking before meal for 3 times per day, for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boesenbergia
Description: Boesenbergia extract, equivalent to pinostrobin 30 mg per capsule, for a total of 180 mg of pinostrobin per day, dosing into 2 capsules taking after meal for 3 times per day for 5 days.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard supportive treatment
Description: as recommended by guidelines from the Ministry of Public Health, Thailand. No antivirus was given.
Study: NCT06327269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib 10 mg
Description: Lenvatinib would be used on patients with advanced liver cancer after Liver transplantation as an adjuvant treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib 10 mg
Description: Lenvatinib would be used on patients with advanced liver cancer after Liver transplantation as an adjuvant treatment.
Study: NCT05270720

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell
Description: Biological: Dendritic Cell Immunotherapy Adult patients with histopathologically diagnosed Ovarian Cancer will be eligible for this novel, personalized dendritic cell vaccine during course of standard of care chemotherapy.~If unacceptable side effects are observed at a total dose of 5x106, as detailed in the study protocol, then a cohort of 3-6 enrolled patients will receive a de-escalated total dendritic cell dose of 2.5x106.~If no unacceptable side effects are identified at a total dose of 5x106, as detailed in the study protocol, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 1X107.
Study: NCT06271577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AliveCor 12-lead ECG
Description: The primary objective of this study is to determine if the AliveCor 12-lead Smartphone ECG is an acceptable substitute for a standard 12-lead ECG in the identification of STEMI and NSTEMI.
Study: NCT05533606

Intervention type: DRUG
Intervention: Beta-Lactam Drugs
Description: During hospitalization，patients used Beta-Lactam drugs.

Intervention type: DRUG
Intervention: Beta-Lactam Drugs
Description: During hospitalization，patients used Beta-Lactam drugs.
Study: NCT05371626

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Suture-less surgical procedure
Description: Suture-less technique will be used in treatment for cicatricial upper eyelid entropion
Study: NCT05939882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low concentration atropine (0.01%)
Description: low concentration atropine (0.01%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low concentration atropine (0.02%)
Description: low concentration atropine (0.02%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low concentration atropine (0.04%)
Description: low concentration atropine (0.04%)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drop
Study: NCT04909996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentinox--Group A
Description: GROUP A: Sentinox treatment performed 3 times/day for 5 days (as addon to the standard therapy) at 8am, 2pm and 8pm;~The application of IP on should be performed in accordance to the following indication:~The treatment is administered in a dose of 0.5 ml into each nostril (5 sprays) per the number of times per day according the trial group assigned according the randomization procedure (i.e., GROUP A: 3 times/day; GROUP B: 5 times/day; GROUP C: no IP treatment).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentinox--Group B
Description: GROUP B: Sentinox treatment performed 5 times/day for 5 days (as addon to the standard therapy) at 8am, 11am, 2pm, 5pm and 8pm;~The application of IP on should be performed in accordance to the following indication:~The treatment is administered in a dose of 0.5 ml into each nostril (5 sprays) per the number of times per day according the trial group assigned according the randomization procedure (i.e., GROUP A: 3 times/day; GROUP B: 5 times/day; GROUP C: no IP treatment).
Study: NCT04312178

Intervention type: OTHER
Group type: OTHER
Intervention: cash incentive
Description: cash incentive (20€ gift card)

Intervention type: OTHER
Group type: OTHER
Intervention: cash incentive
Description: cash incentive (20€ gift card)

Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Group type: OTHER
Intervention: return vaginal self-swab kit in person
Description: hand-delivered to a health care professional to encourage discussion of cervical cancer prevention

Intervention type: OTHER
Group type: OTHER
Intervention: return vaginal self-swab kit in person
Description: hand-delivered to a health care professional to encourage discussion of cervical cancer prevention
Study: NCT05625113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuroprosthesis
Description: Use at least one time every day the gripping neuroprosthesis in daily life activities.
Study: NCT05129553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Béa Applicator and Béa Cervical Cap Device
Description: Single-use of the investigational device